Kyverna Therapeutics

Founded in 2018, we are a clinical-stage biopharmaceutical company focused on biotechnology research. We develop patient-centered cell therapies for people with autoimmune diseases.

Our lead product candidate, KYV-101, is in clinical development, with Phase 2 trials for stiff-person syndrome, multiple sclerosis, and myasthenia gravis, and a Phase ¹⁄₂ trial for systemic sclerosis. We also have two ongoing multi-center, open-label Phase ¹⁄₂ trials in the United States and Germany for patients with lupus nephritis.

Our pipeline also includes next-generation chimeric antigen receptor (CAR) T-cell therapies, available in both autologous and allogeneic formats, designed for B cell-driven autoimmune diseases. We aim for deep B cell depletion, immune system reset, and long-term remission, as we believe CAR T-cell therapy can reset the immune system after a single infusion.

The process involves collecting a patient’s blood, separating T cells, and altering them to recognize and destroy B cells. These altered CAR T cells are then infused back into the patient. They target B cells to control, reduce, or reverse the disease, allowing the body to replenish with healthy B cells.

We consider requests for expanded access to our investigational products when alternative therapy options have been exhausted. We are located in Emeryville, CA.

Our mission is to liberate autoimmune patients through the potential of cell therapy. This mission guides our core values:

We “Stay True to Why” by serving patients and transforming lives through high standards of excellence and integrity.

We “Collaborate to Accelerate” by emphasizing intentional, efficient collaboration, courageous conversations, and building bridges across teams. This fosters innovation and helps us achieve results with agility and resilience.

Through “Lead with Clarity,” we aim to build trust and alignment. We communicate clearly and candidly, sharing the “why” behind decisions to ensure transparency and mutual understanding.

We “Boldly Innovate” by adapting, staying ambitious, operating with urgency, and continuously pushing boundaries.

Finally, we “Own the Outcome” by fostering a culture of shared accountability where learning is celebrated. We model vulnerability and empower individuals to speak up and take risks, which leads to outstanding results and mutual support.

We have 51-200 employees. Our culture is defined by intellectually curious, collaborative individuals who are committed to our patients and share a passion for continuous improvement.

Our environment is supportive, uplifting, and intellectually stimulating. We focus on scientific breakthroughs, collaboration, and transforming medicine for autoimmune disease.

Our team members appreciate the openness and transparency from leadership, which encourages tackling new challenges and fosters a creative atmosphere. Collaboration is foundational; we emphasize open interaction across teams and platforms.

We support continuous learning and offer opportunities for career development within our growing structure.

We offer a comprehensive package of employee benefits and perks.

Our time-off benefits include unlimited flexible PTO, holidays, and a winter shutdown, alongside a flexible (hybrid) work environment.

Our comprehensive well-being benefits include:

• Generous company-subsidized medical, dental, and vision insurance
• Employee Assistance Program (EAP)
• Parental leave
• Commuter assistance program
• Onsite gym
• Legal protection
• Identity theft programs
• Various discount programs

For financial security and future savings, we provide:

• Competitive base salaries and bonus structures
• 401(k) retirement with company match
• Equity grants
• Flexible Spending Accounts (FSA)
• Health Savings Accounts (HSA)
• Group life and disability insurance

Employees are also eligible for annual bonuses and participation in our stock option plan.